Biogen Idec and Eisai form new manufacturing alliance
Biogen Idec is to lease a portion of Eisai's RTP facility, where it will manufacture oral solid dose products.
Biogen Idec has announced a manufacturing alliance with Eisai Inc, based at the Research Triangle Park (RTP) in the US.
Both companies already have facilities at the park, and Biogen Idec will now lease a portion of Eisai's facility to manufacture oral solid dose products for both companies.
Eisai will provide vial-filling services for biologic therapies and packaging services for oral solid dose products, with Biogen Idec having the option to purchase the Eisai oral solid dose facility under the ten-year lease agreement.
John Cox, executive vice-president of pharmaceutical operations and technology at Biogen Idec, commented: "This innovative capacity-sharing relationship with Eisai fits strategically in our global drug supply network, particularly as we advance our oral therapeutics."
Lou Arp, general manager of Eisai's RTP site and president of global oncology manufacturing, said that he looks forward to collaborating with Biogen Idec.
He claimed that the alliance will enable both companies to focus on their respective areas of expertise, while continuing to deliver "high-quality and innovative products".
"Moreover, employees will benefit by working in a highly collaborative environment that offers opportunities to further cultivate their careers," he added.
As part of the agreement, approximately 50 of Eisai's employees will join Biogen Idec's workforce, which already numbers 1,000-plus.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance